EGFR and non-small cell lung carcinoma: Mechanistically, EGFR TKIs attenuated lysosomal acidification owing to their intrinsic alkalinity, and the modification of gefitinib to diminish its alkalinity led to an enhanced inhibitory effect on NSCLC compared with parental gefitinib.